A rare case of double recurrent choroidal melanoma, with distinctive immunohistochemical features

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 1, 2010, Pages 187-193

  Indrei, Anca ^a   Cianga, P ^a   Florea, Irina D ^a   Haba, Danisia ^a   Foia, Liliana ^a   Cianga, Corina M ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Aggressiveness; Choroidal melanoma; Double recurrence

Indexed keywords

TUMOR MARKER;

ARTICLE; CASE REPORT; CHOROID TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; CHOROID NEOPLASMS;

CHOROID NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MIDDLE AGED; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 77949408039     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Phillpotts BA, Sanders RJ, Shields JA, Griffiths JD, Augsburger JA, Shields CL, Uveal melanomas in black patients: a case series and comparative review, J Natl Med Assoc, 1995, 87(9):709-714.
2. Kanthan GL, Grigg J, Billson F, Kourt G, Conway RM, Paediatric uveal melanoma, Clin Experiment Ophthalmol, 2008, 36(4):374-376.
3. Lindegaard J, Isager P, Prause JU, Heegaard S, Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern, Invest Ophtalmol Vis Sci, 2006, 47(8):3268-3275.
4. Isager P, Ehlers N, Overgaard J, Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas, Acta Ophtalmol Scand, 2004, 82(5):517-525.
5. Mittica N, Vemuganti GK, Duffy M, Torczynski E, Edward DP, Late orbital recurrence of a choroidal melanoma following internal resection: report of a case and review of the literature, Surv Ophthalmol, 2003, 48(2):181-190.
6. Shields JA, Augsburger JJ, Donoso LA, Bernardino VB Jr, Portenar M, Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years, Am J Ophthalmol, 1985, 100(5):666-668.
7. Ross JJ, Dean SJ, Koppel DA, Roberts F, Kemp EG, Massive orbital recurrence of uveal melanoma without metastases after 28 years, Br J Ophthalmol, 2008, Oct 29 [Epub ahead of print].
8. Affeldt JC, Minckler DS, Azen SP, Yeh L, Prognosis in uveal melanoma with extrascleral extension, Arch Ophthalmol, 1980, 98(11):1975-1979.
9. Magro CM, Crowson AN, Mihm MC, Unusual variants of malignant melanoma, Mod Pathol, 2006, 19 Suppl 2:S41-S70.
10. Anstey A, Cerio R, Ramnarain N, Orchard G, Smith N, Jones EW, Desmoplastic malignant melanoma. An immu-nocytochemical study of 25 cases, Am J Dermatopathol, 1994, 16(1):14-22.
11. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL Jr et al, Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential, J Natl Cancer Inst, 1992, 84(3):165-174.
12. Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R, Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers, Lab Invest, 1998, 78(2):153-163.
13. Seregard S, Spångberg B, Juul C, Oskarsson M, Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma, Ophthalmology, 1998, 105(3):485-491.
14. Sherr CJ, Roberts JM, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev, 1999, 13(12):1501-1512.
15. Schwandner O, Bruch HP, Broll R, p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance?, Int J Colorectal Dis, 2002, 17(1):11-19.
16. Mouriaux F, Maurage CA, Labalette P, Sablonnière B, Malecaze F, Darbon JM, Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors, Invest Ophthalmol Vis Sci, 2000, 41(10):2837-2843.
17. Nagata S, Golstein P, The Fas death factor, Science, 1995, 267(5203):1449-1456.
18. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J, Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape, Science, 1996, 274(5291):1363-1366.
19. Nagata S, Fas-induced apoptosis, and diseases caused by its abnormality, Genes Cells, 1996, 1(10):873-879.
20. Cooper K, Haffajee Z, bcl-2 and p53 protein expression in follicular lymphoma, J Pathol, 1997, 182(3):307-310.
21. Vojtě;šek B, Bártek J, Midgley CA, Lane DP, An immuno-chemical analysis of the human nuclear phospho-protein p53. New monoclonal antibodies and epitope mapping using recombinant p53, J Immunol Methods, 1992, 151(1-2):237-244.
22. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P, Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells, Lab Invest, 1993, 69(4):415-429.
23. Ioachim E, Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features, Int J Clin Pract, 2008, 62(11):1736-1743.
24. Ferguson TA, Griffith TS, A vision of cell death: Fas ligand and immune privilege 10 years later, Immunol Rev, 2006, 213:228-238.
25. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA, Fas ligand-induced apoptosis as a mechanism of immune privilege, Science, 1995, 270(5239):1189-1192.
26. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F, The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand, J Exp Med, 1996, 184(3):1075-1082.
27. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U, Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer, Br J Cancer, 2001, 85(7):1047-1054.
28. Al-Jamal RT, Mäkitie T, Kivelä T, Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body, Invest Ophthalmol Vis Sci, 2003, 44(6):2381-2389.
29. Dusek RL, Godsel LM, Green KJ, Discriminating roles of desmosomal cadherins: beyond desmosomal adhesion, J Dermatol Sci, 2007, 45(1):7-21.
30. Rickelt S, Franke WW, Doerflinger Y, Goerdt S, Brandner JM, Peitsch WK, Subtypes of melanocytes and melanoma cells distinguished by their intercellular contacts: heterotypic adherens junctions, adhesive associations, and dispersed desmoglein 2 glycoproteins, Cell Tissue Res, 2008, 334(3):401-422.
31. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE, Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry, Proc Natl Acad Sci U S A, 2001, 98(14):8018-8023.
32. Kukacka J, Průsa R, Kotaska K, Pelouch V, Matrix metallo-proteinases and their function in myocardium, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2005, 149(2):225-236.